Show Summary Details
Page of

Opioid therapy: optimizing analgesic outcomes 

Opioid therapy: optimizing analgesic outcomes
Opioid therapy: optimizing analgesic outcomes

Marie T. Fallon

and Nathan I. Cherny

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 January 2022

Treatment with analgesic drugs is the mainstay of cancer pain management. The major group of drugs used in cancer pain management is the opioid analgesics. During the last 30 years, there has been a dramatic increase in our knowledge of the sites and mechanism of action of the opioids. The development of analytical methods has also been of great importance in facilitating pharmacokinetic studies of the disposition and fate of opioids in patients. More recently, advances in genomic research have indicated the potential importance of pharmacogenetic factors in the response to opioid analgesics. These studies have begun to offer us a better understanding of some of the sources of variation between individuals in their response to opioids and to suggest ways of minimizing some of their adverse effects. This chapter presents a comprehensive discussion of the pre-clinical pharmacology and clinical aspects of opioid analgesia and the principles of opioid administration.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.